AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6175933 — intervention group
Group type: COMPARATOR
Intervention: Secondary chemotherapy (sc)
Number of subjects: 33
Study 30859909 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Navigators (NNs)
Number of subjects: 100
Study 30859909 — intervention group
Group type: COMPARATOR
Intervention: Historical Control Group
Number of subjects: 100
Study 30859909 — intervention group
Group type: COMPARATOR
Intervention: Concurrent Control Group
Number of subjects: 100
Study 30227301 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione 30 mg L-1
Number of subjects: 6
Study 30227301 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione 50 mg L-1
Number of subjects: 6
Study 30227301 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione 40 mg L-1
Number of subjects: 6
Study 30227301 — intervention group
Group type: COMPARATOR
Intervention: Glutathione 0 mg L-1 (control)
Number of subjects: 6
Study 26946727 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion (once a day, 15-20 min each time, till local skin turned slightly red)
Number of subjects: 40
Study 26946727 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (0.3 g twice a day), Methotrexate (10 mg once a week), Folic acid (5 mg once a week)
Number of subjects: 40
Study 24799543 — intervention group
Group type: EXPERIMENTAL
Intervention: Advergame promoting energy-dense snacks
Number of subjects: 261
Study 24799543 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewarding children to refrain from eating
Number of subjects: 261
Study 24799543 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewarding impulsive children to refrain from eating while playing an advergame promoting energy-dense snacks
Number of subjects: 261
Study 24799543 — intervention group
Group type: EXPERIMENTAL
Intervention: Rewarding low impulsive children to refrain from eating while playing nonfood advergames
Number of subjects: 261
Study 21795756 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular walking exercise for 6 months
Number of subjects: 40
Study 21795756 — intervention group
Group type: COMPARATOR
Intervention: Usual physical activity (control group)
Number of subjects: 40
Study 21795756 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate supplementation (target venous bicarbonate 29 mmol/L)
Number of subjects: 40
Study 21795756 — intervention group
Group type: COMPARATOR
Intervention: Previous sodium bicarbonate treatment (target 24 mmol/L)
Number of subjects: 40
Study 19955221 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint lavage alone
Number of subjects: 855
Study 19955221 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint lavage combined with IA steroid injection
Number of subjects: 855
Study 19955221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 855
Study 17363740 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 758
Study 17363740 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 758
Study 17363740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 758
Study 16324030 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg.kg(‐1)
Number of subjects: 120
Study 16324030 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 120
Study 12151918 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated pathway (n = 131)
Number of subjects: 201
Study 12151918 — intervention group
Group type: COMPARATOR
Intervention: Standard pathway (n = 70)
Number of subjects: 201
Study 12151918 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison
Number of subjects: 201
Study 12151918 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 201
Study 10445610 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 2 mg x day(-1)
Number of subjects: 44
Study 10445610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 7823712 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 2295
Study 7823712 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 2295
Study 7823712 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe carotid stenosis (70-99%)
Number of subjects: 2295
Study 7823712 — intervention group
Group type: COMPARATOR
Intervention: Overall stroke risk
Number of subjects: 2295
Study 2192383 — intervention group
Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 210
Study 2192383 — intervention group
Group type: EXPERIMENTAL
Intervention: dothiepin
Number of subjects: 210
Study 2192383 — intervention group
Group type: COMPARATOR
Intervention: placebo tablets
Number of subjects: 210
Study 2192383 — intervention group
Group type: EXPERIMENTAL
Intervention: cognitive and behaviour therapy
Number of subjects: 210
Study 2192383 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐help package
Number of subjects: 210
Study 476023 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin (100,000 units/day for 14 days)
Number of subjects: 0
Study 476023 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole (100 mg/day for 6 days)
Number of subjects: 0
Study 476023 — intervention group
Group type: COMPARATOR
Intervention: Miconazole (100 mg/day for 14 days)
Number of subjects: 0
Study 476023 — intervention group
Group type: COMPARATOR
Intervention: Miconazole (100 mg twice daily for 7 days)
Number of subjects: 0
Study 31987323 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/kg VE
Number of subjects: 180
Study 31987323 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg/kg VE
Number of subjects: 180
Study 31987323 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg/kg VE
Number of subjects: 180
Study 31987323 — intervention group
Group type: EXPERIMENTAL
Intervention: 640 mg/kg VE
Number of subjects: 180
Study 31013292 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenge appraisal condition featuring orienting information describing benefits of persistence despite discomfort for future life satisfaction
Number of subjects: 235
Study 31013292 — intervention group
Group type: COMPARATOR
Intervention: Higher threat appraisal condition featuring task orienting information describing symptoms and consequences of frostbite
Number of subjects: 235
Study 31013292 — intervention group
Group type: COMPARATOR
Intervention: Lower threat appraisal condition featuring orienting information about safety of the CPT
Number of subjects: 235
Study 27995821 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted reflection on life events and ultimate life goals
Number of subjects: 45
Study 25885634 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized exercise intervention trial on cancer‐related fatigue
Number of subjects: 117
Study 24062180 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar (ZYH1) at doses of 0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 32, 64, and 128 mg
Number of subjects: 96
Study 24062180 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar (1 mg)
Number of subjects: 96
Study 24062180 — intervention group
Group type: EXPERIMENTAL
Intervention: Saroglitazar (up to 128 mg)
Number of subjects: 96
Study 22035643 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline treatment
Number of subjects: 469
Study 22035643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 469
Study 19124098 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cement injection into non-fractured vertebra adjacent to fractured vertebra
Number of subjects: 244
Study 19124098 — intervention group
Group type: COMPARATOR
Intervention: Non-prophylactic treatment (no cement injection)
Number of subjects: 244
Study 17848839 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical hyperthyroidism (sHT)
Number of subjects: 24
Study 17848839 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 24
Study 15495732 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mm insole
Number of subjects: 38
Study 15495732 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm insole
Number of subjects: 38
Study 15495732 — intervention group
Group type: COMPARATOR
Intervention: Current-issue Saran insoles
Number of subjects: 38
Study 11694667 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 1.2 mg/kg/day
Number of subjects: 297
Study 11694667 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 1.8 mg/kg/day
Number of subjects: 297
Study 11694667 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 0.5 mg/kg/day
Number of subjects: 297
Study 11694667 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (all doses)
Number of subjects: 297
Study 11694667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study 8981385 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.5 mg i.v.)
Number of subjects: 12
Study 8981385 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg p.o.)
Number of subjects: 12
Study 8981385 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline (4 mg p.o.)
Number of subjects: 12
Study 8981385 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg p.o.) + Scopolamine (0.5 mg i.v.)
Number of subjects: 12
Study 8981385 — intervention group
Group type: EXPERIMENTAL
Intervention: Metergoline (4 mg p.o.) + Scopolamine (0.5 mg i.v.)
Number of subjects: 12
Study 8981385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8518376 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted continuous infusion (CACI)
Number of subjects: 24
Study 8518376 — intervention group
Group type: COMPARATOR
Intervention: Manual controlled infusion (MCI)
Number of subjects: 24
Study 8518376 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 2881575 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dimethindene maleate
Number of subjects: 16
Study 31236568 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA-Slim (MTX, prednisone step-down from 30 mg)
Number of subjects: 379
Study 31236568 — intervention group
Group type: COMPARATOR
Intervention: COBRA-Classic (MTX, sulfasalazine, prednisone step-down from 60 mg)
Number of subjects: 379
Study 31236568 — intervention group
Group type: COMPARATOR
Intervention: COBRA-Avant-Garde (MTX, leflunomide, prednisone step-down from 30 mg)
Number of subjects: 379
Study 31236568 — intervention group
Group type: COMPARATOR
Intervention: Tight Step Up (TSU) (MTX without prednisone)
Number of subjects: 379
Study 31236568 — intervention group
Group type: COMPARATOR
Intervention: COBRA-Classic
Number of subjects: 379
Study 31236568 — intervention group
Group type: COMPARATOR
Intervention: COBRA-Avant-Garde
Number of subjects: 379
Study 27834686 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg) and folic acid (0.8 mg)
Number of subjects: 10783
Study 27834686 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 mg) alone
Number of subjects: 10783
Study 26623405 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron (Group O)
Number of subjects: 90
Study 26623405 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone (Group D)
Number of subjects: 90
Study 26623405 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron + 8 mg dexamethasone (Group OD)
Number of subjects: 90
Study 26623405 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 90
Study 23993109 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (bemiparin) for 10 days at a prophylactic dose, early ambulation, and compression therapy for 3 months
Number of subjects: 262
Study 23993109 — intervention group
Group type: COMPARATOR
Intervention: Early ambulation and compression therapy alone
Number of subjects: 262
Study 21533663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracuff pressure of 80 cm H(2)O
Number of subjects: 123
Study 21533663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracuff pressure of 60 cm H(2)O
Number of subjects: 123
Study 21533663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracuff pressure of 40 cm H(2)O
Number of subjects: 123
Study 21533663 — intervention group
Group type: COMPARATOR
Intervention: Postoperative pharyngolaryngeal adverse events
Number of subjects: 123
Study 21533663 — intervention group
Group type: COMPARATOR
Intervention: Patient satisfaction scores
Number of subjects: 123
Study 21533663 — intervention group
Group type: COMPARATOR
Intervention: Anesthesiologist satisfaction scores
Number of subjects: 123
Study 18194979 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80-160 mg/d)
Number of subjects: 68
Study 18194979 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (50-100 mg/d)
Number of subjects: 68
Study 16490024 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg daily)
Number of subjects: 12
Study 16490024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 14992341 — intervention group
Group type: EXPERIMENTAL
Intervention: Active FES‐assisted standing (AS)
Number of subjects: 15
Study 14992341 — intervention group
Group type: COMPARATOR
Intervention: Frame‐supported passive standing (PS)
Number of subjects: 15
Study 11121916 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg
Number of subjects: 80
Study 11121916 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 2600 mg
Number of subjects: 80
Study 11121916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8970342 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 micrograms twice a day)
Number of subjects: 12
Study 8970342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8970342 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice a day)
Number of subjects: 12
Study 1306041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 3 ml 1%
Number of subjects: 28
Study 1306041 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline 3 ml
Number of subjects: 28
Study 6391418 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education group (receiving standard inpatient medical care + formal education program)
Number of subjects: 22
Study 6391418 — intervention group
Group type: COMPARATOR
Intervention: Control group (receiving only standard inpatient medical care)
Number of subjects: 22
Study 6391418 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education group
Number of subjects: 22
Study 6391418 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 30458263 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (awareness of alcohol consumption focus)
Number of subjects: 5478
Study 30458263 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (additional questions on alcohol use)
Number of subjects: 5478
Study 30458263 — intervention group
Group type: COMPARATOR
Intervention: Group A (control group, lifestyle survey only)
Number of subjects: 5478
Study 29891726 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mail materials and a $20 incentive for screening
Number of subjects: 116407
Study 25627152 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy
Number of subjects: 131
Study 25627152 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 131
Study 23846809 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects
Number of subjects: 568
Study 23846809 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects with neuropathy
Number of subjects: 568
Study 23846809 — intervention group
Group type: EXPERIMENTAL
Intervention: NSE levels
Number of subjects: 568
Study 23846809 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cutoff point for serum NSE levels
Number of subjects: 568
Study 21288803 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavac(®) (new vaccine)
Number of subjects: 484
Study 21288803 — intervention group
Group type: COMPARATOR
Intervention: Easyfive(®) (available in the market)
Number of subjects: 484
Study 19918088 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered collaborative care
Number of subjects: 302
Study 19918088 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 302
Study 16450340 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 404
Study 16450340 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline 2 mg/day
Number of subjects: 404
Study 16450340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 14992912 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 U of fresh frozen plasma (FFP)
Number of subjects: 20
Study 14992912 — intervention group
Group type: COMPARATOR
Intervention: No fresh frozen plasma (no FFP)
Number of subjects: 20
Study 11401627 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-beta-1a
Number of subjects: 0
Study 12318240 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg)
Number of subjects: 46
Study 12318240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 12318240 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 46
Study 3303244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramified amino acids (24 g in a 750 ml solution) infused daily for 10 days
Number of subjects: 20
Study 3303244 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol (5% solution, 750 ml) infused daily for 10 days
Number of subjects: 20
Study 28776922 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous exendin (9-39) injection
Number of subjects: 9
Study 26922904 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐learning educational program
Number of subjects: 697
Study 26922904 — intervention group
Group type: COMPARATOR
Intervention: basic geriatric pharmacology notions (Control)
Number of subjects: 697
Study 26205091 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (n=8)
Number of subjects: 18
Study 26205091 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (n=10)
Number of subjects: 18
Study 26205091 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 18
Study 26205091 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 18
Study 23419098 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent mandatory ventilation (NIMV)
Number of subjects: 40
Study 23419098 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 40
Study 21138693 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with thoracic epidural anesthesia (Group A)
Number of subjects: 120
Study 21138693 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (Group B)
Number of subjects: 120
Study 18234554 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of MMP-2 and TIMP-1
Number of subjects: 184
Study 18234554 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of MMP-9
Number of subjects: 184
Study 18234554 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II, epinephrine, norepinephrine
Number of subjects: 184
Study 16464887 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line haemodiafiltration with acetate (3 mmol/l)
Number of subjects: 12
Study 16464887 — intervention group
Group type: COMPARATOR
Intervention: On-line haemodiafiltration without acetate
Number of subjects: 12
Study 16464887 — intervention group
Group type: EXPERIMENTAL
Intervention: On-line haemodiafiltration with acetate
Number of subjects: 12
Study 12694711 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who agreed to participate in the clinical trial
Number of subjects: 0
Study 12694711 — intervention group
Group type: COMPARATOR
Intervention: Patients who refused to participate in the clinical trial
Number of subjects: 0
Study 10610746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amiodarone 400 mg/day for 1 month before and 200 mg/day for 2 months after cardioversion
Number of subjects: 92
Study 10610746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diltiazem 180 mg/day for 1 month before and 2 months after cardioversion and potassium infusion
Number of subjects: 92
Study 10610746 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral diltiazem 180 mg/day for 1 month before and 2 months after cardioversion)
Number of subjects: 92
Study 9093005 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide 0.25 pmol min‐1 kg‐1
Number of subjects: 8
Study 9093005 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide 0.5 pmol min‐1 kg‐1
Number of subjects: 8
Study 9093005 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain natriuretic peptide 0.5 pmol min‐1 kg‐1 with SCH 32615 pretreatment
Number of subjects: 8
Study 8436001 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel triphasic (LNG)
Number of subjects: 300
Study 8436001 — intervention group
Group type: COMPARATOR
Intervention: Norethindrone triphasic (NET)
Number of subjects: 300
Study 8436001 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 300
Study 3529953 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aspirin (325 mg)
Number of subjects: 33
Study 3529953 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin (325 mg)
Number of subjects: 33
Study 3529953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 29432648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg, 10 drops orally, three times daily for 12 weeks)
Number of subjects: 72
Study 29432648 — intervention group
Group type: COMPARATOR
Intervention: Artificial saliva (10 drops orally, three times daily for 12 weeks)
Number of subjects: 72
Study 26678717 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular taping (NMT) and standard physical therapy programme (SPTP)
Number of subjects: 32
Study 26678717 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy programme (SPTP)
Number of subjects: 32
Study 24476472 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Number of subjects: 12
Study 24476472 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, isovolumetric placebo control orange juice
Number of subjects: 12
Study 22820158 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga exercise session
Number of subjects: 30